CTKB Cytek Biosciences, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1831915 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.5%
TTM net income YoY-533.4%
TTM EPS YoY-519.7%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR—
Margins
Gross margin54.7%
Operating margin-21.1%
Net margin-39.1%
FCF margin-6.5%
EBITDA margin-18.2%
Returns
ROE-23.2%
ROA-17.3%
ROIC (approx.)-12.8%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets28.0%
Debt / equity0.00x
Current ratio4.46x
Interest coverage-562.56x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-15.9%
Payout ratio—
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $53.23M | $48.14M | $44.13M | $62.14M | $52.29M | $45.60M | $41.46M | $57.48M |
| Cost of revenue | $22.02M | $19.80M | $22.88M | $29.26M | $24.74M | $21.73M | $21.30M | $23.82M |
| Gross profit | $31.21M | $28.34M | $21.25M | $32.88M | $27.55M | $23.87M | $20.16M | $33.65M |
| R&D expense | $9.36M | $9.74M | $9.60M | $8.96M | $8.96M | $8.83M | $9.72M | $9.72M |
| SG&A expense | $18.36M | $16.82M | $18.47M | $16.39M | $16.12M | $13.53M | $12.90M | $9.07M |
| Operating income | -$8.42M | -$11.40M | -$18.46M | -$5.59M | -$9.19M | -$10.62M | -$14.97M | $2.99M |
| Interest expense | $260,000 | $281,000 | $262,000 | -$725,000 | $494,000 | $414,000 | $291,000 | -$5.93M |
| Pretax income | — | — | — | -$4.03M | -$7.77M | -$6.78M | -$11.27M | $10.32M |
| Income tax | -$811,000 | $515,000 | $1.49M | $40.05M | -$2.29M | -$1.19M | $136,000 | $680,000 |
| Net income | -$6.10M | -$12.16M | -$18.87M | -$44.08M | -$5.48M | -$5.58M | -$11.40M | $9.64M |
| EBITDA | -$7.22M | -$10.30M | -$16.60M | -$3.70M | -$8.19M | -$9.62M | -$13.10M | $4.84M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Weighted avg. shares (diluted) | 130.36M | 129.46M | 128.70M | — | 127.55M | 126.93M | 128.34M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $66.81M | $73.85M | $65.67M | $90.85M | $93.28M | $75.47M | $95.30M | $98.75M |
| Receivables | $59.19M | $49.70M | $51.90M | $62.51M | $56.63M | $56.23M | $55.03M | $60.59M |
| Inventory | $52.37M | $52.25M | $49.79M | $48.43M | $51.65M | $49.49M | $45.35M | $43.89M |
| Current assets | $378.94M | $377.93M | $379.30M | $392.00M | $388.49M | $382.82M | $380.50M | $396.45M |
| PP&E, net | $20.61M | $20.80M | $20.47M | $18.01M | $18.05M | $18.35M | $17.83M | $17.96M |
| Goodwill | $16.69M | $16.69M | $16.69M | $16.70M | $16.70M | $16.71M | $16.68M | $16.66M |
| Intangibles | $14.03M | $14.87M | $15.70M | $16.82M | $17.68M | $18.60M | $19.43M | $20.13M |
| Total assets | $446.14M | $446.93M | $449.11M | $461.54M | $494.92M | $493.32M | $482.60M | $499.50M |
| Current liabilities | $84.95M | $84.33M | $80.94M | $77.80M | $75.21M | $73.27M | $67.69M | $67.66M |
| Total liabilities | $124.79M | $124.98M | $121.47M | $119.80M | $116.35M | $115.76M | $102.97M | $103.76M |
| Shareholders' equity | $321.35M | $321.95M | $327.64M | $341.74M | $378.57M | $377.56M | $379.62M | $395.74M |
| Shares outstanding | 130.77M | 129.98M | 129.14M | 128.55M | 127.86M | 127.19M | 127.60M | 129.21M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.45M | $1.37M | -$2.74M | -$771,000 | -$3.90M | $108,000 | -$125,000 | $2.00M |
| Capital expenditure | $1.51M | $2.22M | $2.17M | $1.00M | $657,000 | $1.58M | $849,000 | $894,000 |
| Free cash flow | -$5.96M | -$849,000 | -$4.90M | -$1.77M | -$4.55M | -$1.47M | -$974,000 | $1.10M |
| Investing cash flow | -$1.80M | $7.02M | -$27.08M | -$1.84M | $18.92M | -$16.41M | $9.45M | -$63.43M |
| Financing cash flow | -$561,000 | -$814,000 | $3.98M | -$1.23M | $1.94M | -$2.60M | -$11.54M | -$3.64M |
| Depreciation & amortization | $1.20M | $1.10M | $1.86M | $1.90M | $1.00M | $1.00M | $1.88M | $1.85M |
| Stock-based compensation | $4.85M | $5.34M | $4.86M | $5.53M | $5.64M | $6.79M | $6.63M | $7.00M |
| Share buybacks | $0 | $0 | $0 | -$34,000 | -$29,000 | $4.51M | $10.63M | $7.00M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.